New Potent DOT1L Inhibitors for <i>in Vivo</i> Evaluation in Mouse
作者:Frédéric Stauffer、Andreas Weiss、Clemens Scheufler、Henrik Möbitz、Christian Ragot、Kim S. Beyer、Keith Calkins、Daniel Guthy、Michael Kiffe、Bernard Van Eerdenbrugh、Ralph Tiedt、Christoph Gaul
DOI:10.1021/acsmedchemlett.9b00452
日期:2019.12.12
In MLL-rearranged cancer cells, disruptor of telomeric silencing 1-like protein (DOT1L) is aberrantly recruited to ectopic loci leading to local hypermethylation of H3K79 and consequently misexpression of leukemogenic genes. A structure-guided optimization of a HTS hit led to the discovery of DOT1L inhibitors with subnanomolar potency, allowing testing of the therapeutic principle of DOT1L inhibition in a preclinical mouse tumor xenograft model. Compounds displaying good exposure in mouse and nanomolar inhibition of target gene expression in cells were obtained and tested in vivo.
SHIMADA, KATSUTOSHI;FUJISAKI, HIDEAKI;OKETANI, KIYOSHI;MURAKAMI, MANABU;S+, CHEM. AND PHARM. BULL., 1984, 32, N 12, 4893-4906
N-Alkyl-N'-cyano-N"-(substituted phenyl-pyridinylmethyl) guanidine derivatives were synthesized and tested for inhibitory activity against gastric secretion in rats. Several of the compounds synthesized showed an inhibiting activity as potent as that of cimetidine against basal gastric secretion but showed less potent activity than cimetidine against histamine-stimulated gastric secretion. Some structure-activity relationships are discussed.